Male Breast Cancer Completed Phase 2 Trials for Gefitinib (DB00317)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00024154Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast CancerTreatment